OverviewSuggest Edit

KemPharm is a biopharmaceutical company focused on the discovery and development of new, safer therapies in the areas of pain, ADHD, and other CNS diseases. Its primary efforts include the development of safer, abuse resistant opioid pain relievers. KemPharm’s drug discovery and development platform is based on its proprietary Ligand Activated Therapy (LAT) approach. The Company uses its patent-applied technology to improve existing drugs and shorten the development timeline while still maintaining a strong intellectual property position within each therapeutic area.
TypePublic
Founded2006
HQKissimmee, US
Websitekempharm.com

Latest Updates

Employees (est.) (Dec 2018)33(+4%)
Revenue (FY, 2019)$12.8 M
Share Price (Sept 2020)$0.7 (+2%)
Cybersecurity ratingAMore

Key People/Management at KemPharm

Travis C. Mickle

Travis C. Mickle

President, Chief Executive Officer and Chairman of the Board, Co-Founder
Christal M.M. Mickle

Christal M.M. Mickle

Vice President, Operations and Product Development; Co-Founder
Richard W. Pascoe

Richard W. Pascoe

Lead Independent Director and Chair, Audit Committee
Sven Guenther

Sven Guenther

Executive Vice President, Research and Development
Andrew Barrett

Andrew Barrett

Vice President, Scientific Affairs
Rene A. Braeckman

Rene A. Braeckman

Vice President, Clinical Development
Show more

KemPharm Office Locations

KemPharm has offices in Kissimmee, Blacksburg and Coralville
Kissimmee, US (HQ)
1180 Celebration Blvd #103
Blacksburg, US
2200 Kraft Dr SW STE 2425
Coralville, US
2656 Crosspark Rd #100
Coralville, US
BioVentures Center, 2500 Crosspark Rd e126
Show all (4)

KemPharm Financials and Metrics

KemPharm Revenue

KemPharm's revenue was reported to be $12.84 m in FY, 2019
USD

Revenue (Q2, 2020)

6.9m

Net income (Q2, 2020)

859.0k

EBIT (Q2, 2020)

2.6m

Market capitalization (23-Sept-2020)

51.4m

Closing stock price (23-Sept-2020)

0.7

Cash (30-Jun-2020)

6.4m

EV

113.1m
KemPharm's current market capitalization is $51.4 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

12.8m

Cost of goods sold

10.0m

Gross profit

2.8m

Gross profit Margin, %

22%
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

11.5m2.1m6.9m

Cost of goods sold

1.0m

Gross profit

10.5m

Gross profit Margin, %

91%
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

32.3m16.8m10.9m18.4m3.2m

Accounts Receivable

2.0m140.0k1.7m

Prepaid Expenses

1.7m2.1m1.6m

Inventories

2.8m489.0k
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

10.3m64.2m59.0m77.3m27.5m20.8m12.9m12.4m7.8m8.8m16.5m1.8m13.4m7.3m6.5m2.4m6.4m

Accounts Receivable

2.5m1.5m1.6m2.3m2.1m

Prepaid Expenses

53.0k607.0k607.0k386.0k824.0k636.0k795.0k771.0k1.4m1.8m1.6m2.6m1.9m1.3m528.0k890.0k603.0k

Current Assets

10.3m64.8m59.6m111.4m84.6m65.3m63.0m55.4m50.2m39.1m30.9m16.7m15.3m8.6m8.7m5.5m9.1m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(54.7m)(16.5m)(43.4m)(56.5m)(24.5m)

Depreciation and Amortization

84.0k175.0k336.0k324.0k304.0k

Inventories

(1.2m)(15.9m)

Accounts Payable

1.3m1.1m(801.0k)(1.6m)(3.8m)
USDQ1, 2015

Financial Leverage

-0.3 x
Show all financial metrics

KemPharm Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

KemPharm Online and Social Media Presence

Embed Graph

KemPharm News and Updates

KemPharm Participates in KP415 Mid-Cycle Communication Meeting with FDA

CELEBRATION, Fla., Aug. 14, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the Company participated in a mid-cycle communication meeting on August 13, 2020, with the U.…

KemPharm Announces Issuance of Two Additional U.S. Patents Governing KP415 and KP484

New Patent Issuance Extends SDX Patent Life for an Additional Five Years until 2037

KemPharm Announces Debt Restructuring with Deerfield and Delaware Street Capital

Principal and Interest Payments on Outstanding Debt in Principal Amount of $77.7M Pushed to March 31, 2021; Expected to Extend Cash Runway to New Maturity Date

KemPharm to Present at the 21st Annual Global Investment Conference, Sponsored By H.C. Wainwright & Co.

CELEBRATION, Fla., Sept. 05, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the 21st…

KemPharm Provides Update on APADAZ® Formulary Adoption

Conference Call Scheduled for Today, Wednesday, March 13, 2019 at 8:30 a.m. ET

KemPharm to Present at Upcoming Investor Conferences

CELEBRATION, Fla., March 05, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that management will present at several investor conferences during March 2019.
Show more

KemPharm Blogs

KemPharm to Report First Quarter 2020 Financial Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Tuesday, May 12, 2020 , 5:00 p.m. ET CELEBRATION, Fla. , May 06, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs,

NDA Filing for Potential New ADHD Treatment, KP415, Accepted by FDA; KemPharm Eligible to Receive $5 Million Milestone Payment from Gurnet Point Capital

Corium, GPC’s portfolio company, to lead all commercialization activities for KP415 CELEBRATION, Fla. , May 04, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today confirmed that the U.S.

KemPharm Submits KP415 NDA to the FDA for the Treatment of ADHD

If approved, KemPharm believes that KP415 may address several unmet needs, including earlier onset of action and longer duration of therapeutic effect vs. other available methylphenidate products   Celebration, FL – March 2, 2020 – KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company en…

KemPharm Reports Fourth Quarter and Full-Year 2019 Financial Results

KP415 NDA Remains on Track for Q1 2020 Submission Celebration, FL – February 28, 2020 – KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today provided an update on the KP415 NDA and reported its financial results for…

KemPharm Reports Third Quarter 2019 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, November 14, 2019, at 5:30 p.m. ET   Celebration, FL – November 14, 2019 – KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today rep…

KemPharm to Report Third Quarter 2019 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, November 14, 2019, 5:30 p.m. ET Celebration, FL – November 12, 2019 – KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announ…
Show more

KemPharm Frequently Asked Questions

  • When was KemPharm founded?

    KemPharm was founded in 2006.

  • Who are KemPharm key executives?

    KemPharm's key executives are Travis C. Mickle, Christal M.M. Mickle and Richard W. Pascoe.

  • How many employees does KemPharm have?

    KemPharm has 33 employees.

  • What is KemPharm revenue?

    Latest KemPharm annual revenue is $12.8 m.

  • What is KemPharm revenue per employee?

    Latest KemPharm revenue per employee is $389.1 k.

  • Who are KemPharm competitors?

    Competitors of KemPharm include Atopix, Idera Pharmaceuticals and Akebia Therapeutics.

  • Where is KemPharm headquarters?

    KemPharm headquarters is located at 1180 Celebration Blvd #103, Kissimmee.

  • Where are KemPharm offices?

    KemPharm has offices in Kissimmee, Blacksburg and Coralville.

  • How many offices does KemPharm have?

    KemPharm has 4 offices.